Virica Logo

Virica Biotech Wins Top Abstract Award at ISCT 2022

2022-08-03T09:22:41-04:00

Virica Biotech Awarded Best Abstract at ISCT 2022-San Francisco Our Data Scientist, Andrea Vervoot and VP of Scientific Operations, JonDavid De Jong represented Virica at International Society of Cell & Gene Therapy (ISCT) 2022 in San Francisco. Andrea Vervoot's abstract presentation on the Bioprocess Modelling of Upstream Viral Vector Production Enhancement won the Best Elevator [...]

Virica Biotech Wins Top Abstract Award at ISCT 20222022-08-03T09:22:41-04:00

Virica Biotech Announces Collaboration with the Government of Canada

2022-05-02T07:56:49-04:00

For Immediate Release Virica Biotech Announces Collaboration with the Government of Canada to Make Gene Therapies More Accessible and Affordable for Canadians  Download full press release here. Ottawa, Canada – May 2, 2022 –Virica Biotech Inc. (“Virica”), a leading developer of solutions for scaling of viral medicines, today announced it has received $400,000 from Innovation, [...]

Virica Biotech Announces Collaboration with the Government of Canada2022-05-02T07:56:49-04:00

Virica Biotech Announces R&D Partnership with Oxford BioMedica

2022-02-04T08:52:54-05:00

OTTAWA ,Canada– January 24th, 2022 – Virica Biotech Inc., a leading developer of solutions for scaling of viral medicines, today announced it will collaborate with Oxford BioMedica plc (LSE:OXB), a leading gene and cell therapy company, to improve the yield and production efficiency of Oxford Biomedica's next generation lentiviral vector gene therapies using Virica's [...]

Virica Biotech Announces R&D Partnership with Oxford BioMedica2022-02-04T08:52:54-05:00

Virica Biotech Raises Series A Financing & Expands Operations to Support Clients’ Manufacturing of Viral Medicines

2022-02-04T08:57:31-05:00

OTTAWA – October 4, 2021 – Virica Biotech Inc., a leading life science developer of solutions for scaling of viral medicines, announced today the first closing of its Series A financing. The round, led by Dynamk Capital, is expected to close with additional investors by the end of Q4-2021. The investment strengthens Virica’s already impressive growth [...]

Virica Biotech Raises Series A Financing & Expands Operations to Support Clients’ Manufacturing of Viral Medicines2022-02-04T08:57:31-05:00

Virica Biotech: Enabling Vaccine Development to Fight Against COVID-19

2022-02-04T08:57:13-05:00

March 14, 2020—As the world deals with COVID-19, now officially deemed a pandemic, many groups are racing against the clock to develop vaccines against the novel coronavirus. The development and manufacturing of effective vaccines is a laborious and challenging task for a variety of reasons. In the pandemic situation that we and our loved [...]

Virica Biotech: Enabling Vaccine Development to Fight Against COVID-192022-02-04T08:57:13-05:00
Go to Top